<!DOCTYPE html>
<html>
<head>
  <!-- Site made with Mobirise Website Builder v3.11.1, https://mobirise.com -->
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Mobirise v3.11.1, mobirise.com">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <link rel="shortcut icon" href="assets/images/logo.png" type="image/x-icon">
  <meta name="description" content="Website Builder Description">
  <title>Website Builder Title</title>
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Lora:400,700,400italic,700italic&amp;subset=latin">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Raleway:100,100i,200,200i,300,300i,400,400i,500,500i,600,600i,700,700i,800,800i,900,900i">
  <link rel="stylesheet" href="assets/bootstrap-material-design-font/css/material.css">
  <link rel="stylesheet" href="assets/tether/tether.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="assets/soundcloud-plugin/style.css">
  <link rel="stylesheet" href="assets/dropdown/css/style.css">
  <link rel="stylesheet" href="assets/animate.css/animate.min.css">
  <link rel="stylesheet" href="assets/theme/css/style.css">
  <link rel="stylesheet" href="assets/mobirise/css/mbr-additional.css" type="text/css">
  
  
  
</head>
<body>
<section id="menu-2y">

    <nav class="navbar navbar-dropdown bg-color transparent">
        <div class="container">

            <div class="mbr-table">
                
                <div class="mbr-table-cell">

                    <button class="navbar-toggler pull-xs-right hidden-md-up" type="button" data-toggle="collapse" data-target="#exCollapsingNavbar">
                        <div class="hamburger-icon"></div>
                    </button>

                    <ul class="nav-dropdown collapse pull-xs-right nav navbar-nav navbar-toggleable-sm" id="exCollapsingNavbar"><li class="nav-item"><a class="nav-link link" href="index.html">HOME&nbsp;</a></li><li class="nav-item"><a class="nav-link link" href="Introduction.html">OVERVIEW&nbsp;</a></li><li class="nav-item"><a class="nav-link link" href="Programme.html">PROGRAMME&nbsp;</a></li></ul>
                    <button hidden="" class="navbar-toggler navbar-close" type="button" data-toggle="collapse" data-target="#exCollapsingNavbar">
                        <div class="close-icon"></div>
                    </button>

                </div>
            </div>

        </div>
    </nav>

</section>

<section class="engine"><a rel="external" href="https://mobirise.com">mobirise.com</a></section><section class="mbr-section article mbr-section__container mbr-after-navbar" id="content1-2z" style="background-color: rgb(255, 255, 255); padding-top: 120px; padding-bottom: 0px;">

    <div class="container">
        <div class="row">
            <div class="col-xs-12 lead"><p><strong>The expression pattern of inflammation and redox genes in the blood of mild AD patients – focus on the molecular signatures of NFkB and NRF2&nbsp;</strong></p><p><br></p><p>Gina Manda</p><p><br></p><p>Radiobiology Laboratory, “Victor Babes” National Institute of Pathology, Romania</p><p><strong>Email: </strong>gina.manda@gmail.com</p><p><strong><br></strong></p><p>Besides the association of the Alzheimer’s disease (AD) with profound alterations of the central nervous system, this disease seems to have an echo in blood which might provide valuable peripheral biomarkers for improved diagnosis, prognosis and drug response monitoring. In this context, we performed a targeted transcriptomic study on 38 mild AD patients and 38 matched controls for evaluating the expression levels of 136 inflammation and 84 redox genes in whole blood. Patients were diagnosed as mild AD based on altered levels of total TAU, phospho-TAU and Abeta(1–42) in the cerebrospinal fluid, and Abeta(1–40), Abeta(1–42) and total TAU levels in plasma. We evidenced 48 inflammation and 34 redox genes differentially expressed in the blood of AD patients vs controls (FC&gt;1.5, p&lt;0.01), out of which 22 pro-inflammatory and 12 redox genes exhibited a higher level of up-regulation (FC&gt;2, p&lt;0.001). Using the receiver operating characteristic analysis, we finally selected nine inflammation and seven redox candidate genes that discriminated well between AD patients and controls (area under the curve&gt;0.9). The correlations between the abnormal blood levels of inflammation and redox transcripts in mild AD suggest that RELA might regulate the expression of several redox genes, as for example DUOX1 and GSR. The gene expression pattern revealed that the transcription factors NFκB and NRF2, master regulators of inflammation and redox homeostasis, were significantly disturbed in the blood of AD patients. Concluding, the selected inflammation and redox genes might be useful biomarkers for monitoring antioxidant and anti-inflammatory co-therapies in mild AD. These preliminary results have to be further validated in a larger independent cohort, including investigations at protein level</p><p><br></p></div>
        </div>
    </div>

</section>

<section class="mbr-section" id="msg-box5-30" style="background-color: rgb(255, 255, 255); padding-top: 0px; padding-bottom: 0px;">

    
    <div class="container">
        <div class="row">
            <div class="mbr-table-md-up">

              <div class="mbr-table-cell mbr-right-padding-md-up mbr-valign-top col-md-7 image-size" style="width: 37%;">
                  <div class="mbr-figure"><img src="assets/images/gina-manda-1400x1019.jpg"></div>
              </div>

              


              <div class="mbr-table-cell col-md-5 text-xs-center text-md-left content-size">
                  
                  <div class="lead">

                    <p><strong> Gina Manda </strong>is the head of the Radiobiology laboratory at “Victor Babes” National Institute of Pathology, Bucharest, Romania. She is currently studying the molecular mechanisms underlying: i) low-grade inflammation and disturbed redox signaling in chronic diseases (Alzheimer’s disease), and ii) the responses of normal and tumor cells elicited by radiation exposure in experimental settings relevant for anti-cancer therapies (radio- or photodynamic therapy) or for space medicine. One of the main interests is to develop at preclinical level therapies that target NRF2, in order to: i) increase the efficacy of anti-cancer therapies using targeted NRF2 inhibitors; ii) counteract using NRF2 activators the deleterious effects of galactic cosmic radiation on astronauts during long-term travel in the deep space, an issue that is highly relevant in this era of intensive preparations for space exploration.  </p>

                  </div>

                  
              </div>


              

            </div>
        </div>
    </div>

</section>


  <script src="assets/web/assets/jquery/jquery.min.js"></script>
  <script src="assets/tether/tether.min.js"></script>
  <script src="assets/bootstrap/js/bootstrap.min.js"></script>
  <script src="assets/smooth-scroll/SmoothScroll.js"></script>
  <script src="assets/dropdown/js/script.min.js"></script>
  <script src="assets/touchSwipe/jquery.touchSwipe.min.js"></script>
  <script src="assets/viewportChecker/jquery.viewportchecker.js"></script>
  <script src="assets/theme/js/script.js"></script>
  
  
  <input name="animation" type="hidden">
  </body>
</html>